- Diabetes
- Comparison of Serum PCSK9 Levels in Subjects with Normoglycemia, Impaired Fasting Glucose, and Impaired Glucose Tolerance
-
Eugene Han, Nan Hee Cho, Seong-Su Moon, Hochan Cho
-
Endocrinol Metab. 2020;35(2):480-483. Published online June 24, 2020
-
DOI: https://doi.org/10.3803/EnM.2020.35.2.480
-
-
5,392
View
-
123
Download
-
5
Web of Science
-
5
Crossref
-
 Abstract
 PDF PubReader  ePub
- We investigated proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations in individuals with normoglycemia, impaired fasting glucose (IFG), and impaired glucose tolerance (IGT). This was a pilot, cross-sectional study including 92 individuals who had not been diagnosed with or treated for diabetes. We measured PCSK9 levels in three groups of subjects; namely, normoglycemia (n=57), IFG (n=21), and IGT (n=14). Individuals with IFG and IGT showed higher PCSK9 concentrations than those in the normoglycemic group, with the highest serum PCSK9 concentrations found in individuals with IGT (55.25±15.29 ng/mL for normoglycemia, 63.47±17.78 ng/mL for IFG, 72.22±15.46 ng/mL for IGT, analysis of variance P=0.001). There were no significant differences in high- or low-density lipoprotein cholesterol among groups. Serum PCSK9 levels are increased in patients with prediabetes compared to subjects with normoglycemia.
-
Citations
Citations to this article as recorded by  - Mediation effect of metabolic factors and inflammation on the association of serum uric acid with serum proprotein convertase subtilisin/kexin type 9 levels
Wen Guo, Qin Cui, Zhenzhen Fu, Qun Zhang, Jue Jia
Journal of Clinical Lipidology.2024;[Epub] CrossRef - PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model
Yang Yang, Yeying Wang, Yuwen Wang, Tingyu Ke, Ling Zhao
PeerJ.2024; 12: e17676. CrossRef - Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
Thomas Grewal, Christa Buechler
International Journal of Molecular Sciences.2022; 23(3): 1070. CrossRef - Insight into the Evolving Role of PCSK9
Mateusz Maligłówka, Michał Kosowski, Marcin Hachuła, Marcin Cyrnek, Łukasz Bułdak, Marcin Basiak, Aleksandra Bołdys, Grzegorz Machnik, Rafał Jakub Bułdak, Bogusław Okopień
Metabolites.2022; 12(3): 256. CrossRef - Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis
Susanne Feder, Reiner Wiest, Thomas S. Weiss, Charalampos Aslanidis, Doris Schacherer, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler
Lipids in Health and Disease.2021;[Epub] CrossRef
|
KES
